Podcasts about Biogen

El gobierno de Sánchez vigila a los jueces tras diez feminicidios en 2026, destacando un apuñalamiento en Navarra frente a un menor. El Ministerio de Igualdad elude fallos del sistema Biogen, y la ministra Ana Redondo insta a jueces a ampliar el alejamiento a más de 350 metros. La Policía Nacional afronta críticas tras una denuncia de presunta violación donde la víctima evitó los protocolos internos, acudiendo a un punto violeta y tribunales. Sindicatos alegan fallos si el acusado pertenece a la cúpula, señalando al DAO y sus encubridores. La izquierda radical se reúne en Madrid buscando refundación política, con SUMAR, IU, Comunes y Más Madrid presentes. Notable la ausencia de Yolanda Díaz, Gabriel Rufián y Podemos, este último apostando por perfil propio y criticando priorizar personas sobre proyectos. Donald Trump rediseña su estrategia económica con un gravamen global del 10%, tras la ilegalidad de sus aranceles por el Supremo de EE.UU. Trump critica a los magistrados y ...

Invités :Sylvie Hirrien, directrice communication et engagement patients de Biogen France, et Benoît Bauwens, directeur de l'unité Maladies Rares de Biogen France.https://www.instagram.com/vivre.avec.sma/ https://www.biogen.fr/  1️⃣ Pourquoi créer une page Instagram dédiée à la SMA ? [1'02 – 3'02]✔️ La SMA touche tous les âges et génère un fort besoin d'informations, de partage d'expériences et de lutte contre l'isolement des patients.✔️ 87% des 18-34 ans jugent pertinent de s'informer sur la santé et le bien-être sur les réseaux sociaux.✔️ Les réseaux sociaux permettent d'informer et d'engager les patients.2️⃣ Quelle place l'expérience du quotidien des patients atteints de SMA occupe-t-elle dans cette approche ? [3'03 – 4'25]✔️ Les patients et leurs proches recherchent des informations fiables sur la vie quotidienne avec la SMA.✔️ Biogen a souhaité innover dans la manière de communiquer avec les patients.✔️ La page Instagram vivre.avec.sma fournit des contenus fiables et centrés sur le vécu des patients.3️⃣ Comment définir le ton juste pour parler de cette maladie rare ? [4'26 –6'39]✔️ Un ton accessible et positif, basé sur l'écoute des patients et des experts, pour faciliter le partage d'expérience.✔️ Contenus fiables et rigoureux, garantissant la précision scientifique tout en restant engageants.4️⃣ En quoi une présence structurée sur les réseaux sociaux peut-elle aider les patients à renforcer leur suivi médical ? [6'40 – 8'59]✔️ La page Instagram vivre.avec.sma rappelle l'importance du suivi médical et du lien avec les centres experts.✔️ Elle offre un espace de partage pour aider les patients à se reconnecter à leur parcours de soins.5️⃣ Quels critères ont guidé le choix de l'Agence partenaire pour réaliser ce projet ? [9'00 – 9'55]✔️ Choisir un partenaire ayant une solide connaissance des maladies rares et des formats innovants : Pyramidale Communication.✔️ S'assurer d'un alignement des valeurs et de l'engagement sur la SMA et les maladies rares.6️⃣ Quel rôle joue Arthur Baucheron en tant que parrain de vivre.avec.sma ? [9'56 – 12'09]✔️ Arthur Baucheron incarne la positivité et inspire les jeunes patients SMA.✔️ Il collabore activement à la création de contenus, en facilitant le partage d'expériences et en donnant un visage inspirant à la page.7️⃣ Quelle est l'ambition de vivre.avec.sma auprès des patients atteints de la SMA ? [12'10 – 13'15]✔️ Faire de la page un lieu d'échange et de partage, fédérant une communauté d'entraide autour de contenus positifs et pratiques.✔️ Contribuer à changer la perception de la SMA auprès du grand public, en montrant que les personnes touchées ont en eux une force qui leur permet de surmonter les difficultés du quotidien. L'équipe :Virginie Druenne – Ambassadrice RARE à l'écouteCyril Cassard – Journaliste/AnimationHervé Guillot - ProductionCrédits : Sonacom_________________________________________________RARE à l'écoute est le 1er média d'influence entièrement dédié aux maladies rares :- Un podcast pour faire entendre les voix de celles et ceux qui vivent, soignent et accompagnent ces maladies souvent invisibles.- Les Revues Horizon pour mettre en lumière les meilleures initiatives des centres experts, pour inspirer et connecter les professionnels de santé.- Des Lives engagés, pensés pour les patients, leurs proches et les associations.Un média indépendant, engagé et utile, au service d'un meilleur parcours de soin pour les patients atteints de maladies rares.Toutes nos ressources utiles sont accessibles gratuitement sur : www.rarealecoute.com

Guest Full Name: Dr. R. Stacy Lindborg, PhDGuest Title: President, Chief Executive Officer, and Board DirectorCompany: IMUNONTicker: IMNNWebsite: https://imunon.com/Guest Bio:Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of IMUNON in May 2024. Dr. Lindborg has served on IMUNON's Board of Directors since June 2021. She has nearly 30 years of experience in the pharmaceutical and biotech industries, with a particular focus on R&D, regulatory affairs, executive management, and strategy development. She has designed, hired, and led global teams, guiding long-term visions for growth through analytics and stimulating innovative development platforms to increase productivity.Prior to joining IMUNON, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics, where she remains a member of the company's Board of Directors. At BrainStorm, she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She frequently interacted with investors and analysts, represented the company in the scientific community and with the media, and played an active role in discussions with potential business partners.Dr. Lindborg previously was Vice President and Head of Global Analytics and Data Sciences, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company, where, over the course of 16 years, she assumed positions of increasing responsibility, including Head of R&D strategy.Dr. Lindborg received an MA and PhD in statistics, and a BA in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.Company Bio:IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of diseases. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.IMUNON's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. IMNN-001 is the first therapy to achieve a clinically effective response in advanced (stage IIIC/IV) ovarian cancer including benefits in both progression-free survival (PFS) and overall survival (OS) in a first-line treatment setting when used with standard of care chemotherapy. IMUNON has completed multiple clinical trials evaluating the potential of IMNN-001, including one Phase 2 clinical trial (OVATION 2), and is currently conducting a Phase 3 clinical trial (OVATION 3). The first patient was dosed in the Phase 3 study in the third quarter of 2025. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as IL-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

This INSIGHTS episode revisits a core topic from Neurocritical Care ON CALL®, originally released in August 2023.  Listen to the fourth episode of the NCS INSIGHTS series on acute ischemic stroke (part 2 of 2). The INSIGHTS series is hosted by Casey Albin, MD, and Salia Farrokh, PharmD, and covers topics from Neurocritical Care ON CALL®, the only up-to-date, comprehensive resource dedicated exclusively to the practice of neurocritical care. Learn more about ON CALL®. This episode is sponsored by Biogen. Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen. The NCS Podcast is the official podcast of the Neurocritical Care Society. The views expressed on the NCS Podcast are solely those of the hosts and guests and do not necessarily reflect the opinions or official positions of the Neurocritical Care Society.

Host: Yuval Zabar, MD Guest: Michelle Mielke, PhD Guest: Henrik Zetterberg, MD, PhD For the latest insights on tau and neurodegeneration biomarkers in Alzheimer's disease (AD), tune in to this recorded presentation featuring Doctor Michelle Mielke and Professor Henrik Zetterberg. Together, they delve into the role of tau in AD, exploring the ‘tau cascade', the current use of tau and neurodegeneration biomarkers in tracking disease progression, and how the AD biomarker landscape may evolve over time. Doctor Mielke is a Professor of Epidemiology and Neurology at the Wake Forest University School of Medicine, and Professor Zetterberg is a Professor of Neurochemistry at the University of Gothenburg. To learn more about tau in Alzheimer's disease, explore the Know Tau medical education platform. Know Tau is created and funded by Biogen and is intended for healthcare professionals only.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a fascinating array of stories that highlight the scientific advancements, regulatory updates, and strategic maneuvers shaping our industry.Let's begin with Biogen's efforts to breathe new life into its spinal muscular atrophy treatment, Spinraza. In response to declining sales, Biogen is launching a high-dose version in Japan, aiming to enhance therapeutic efficacy and regain market competitiveness. This move underscores the company's strategy to offset projected revenue declines by 2026. The decision to pursue this high-dose version reflects Biogen's commitment to maintaining its foothold in a challenging market landscape where innovation is key to survival.Shifting gears to regulatory news, the FDA, led by Commissioner Marty Makary, has taken a firm stance against the proliferation of illegal copycat drugs. This announcement comes on the heels of Hims & Hers' controversial introduction of a compounded version of Novo Nordisk's obesity drug, Wegovy. The FDA's commitment to protecting intellectual property and patient safety is crucial in an era where health tech firms increasingly challenge traditional pharmaceutical boundaries. Novo Nordisk's aggressive marketing strategy for Wegovy, including a high-profile Super Bowl advertisement, highlights the competitive pressures in this growing market segment and underscores the legal tensions between established pharma giants and emerging tech-driven companies.In an unexpected turn of events, BridgeBio faced a significant setback as Pfizer withdrew its tafamidis patent in Europe. This led to a notable drop in BridgeBio's stock price and raised concerns about earlier generic entries into the ATTR-CM market. Such developments signal potential shifts in market dynamics and pricing strategies that companies must navigate carefully.On the clinical front, Bayer's phase 3 study of asundexian has demonstrated remarkable results—a 26% reduction in stroke risk. This positions Bayer favorably against competitors Bristol Myers Squibb and Johnson & Johnson, setting a new benchmark in the high-stakes anticoagulant market. Innovation continues to be paramount as companies strive for superior clinical outcomes that can significantly impact patient care.Regulatory landscapes are evolving as well, with Gilead's Yescarta receiving clearance for expanded use. These milestones are crucial for broadening therapeutic indications and enhancing patient access, underscoring ongoing efforts to address unmet medical needs while sustaining growth trajectories.Meanwhile, Pfizer-backed Priovant has reported promising mid-stage results for brepocitinib in treating dermatomyositis and other rare skin conditions. As a TYK2/JAK1 inhibitor, brepocitinib exemplifies precision medicine's expanding role in addressing autoimmune disorders through targeted therapies.The IPO scene remains vibrant with Agomab Therapeutics and Spyglass Pharma making substantial entries into Nasdaq, collectively raising $350 million. This influx indicates continued investor confidence in biopharma innovation despite broader economic uncertainties—a testament to the sector's resilience and potential for groundbreaking advancements.Corporate dynamics are also shifting as seen with Moderna's Chief Medical Officer Jacqueline Miller stepping down after a brief tenure. Leadership changes such as these often signal strategic realignments within companies as they adapt to complex regulatory environments and competitive pressures.Summarizing these developments illustrates a dynamic landscape marked by scientific innovation, regulatory vigilance, and strategic marketing initiatives. As companies strive for competitive advantage through new drug formulations and market expansions, they must also navigate legal challenges and regSupport the show

How do you build an organization that can absorb change, learn from failure, and keep patients at the center—even when the science is uncertain? Nelly Viseux shares lessons from over 20 years in biotech and a decade leading cell and gene therapy development.Nelly discusses how she structured a 100-person CMC organization at Regeneron to balance innovation with operational execution, why documenting your assumptions is critical to managing risk, and what it really takes to maintain resilience when you're literally holding patient lives in your hands.A few of Nelly's key takeaways:Resilience is adaptability—build organizations that absorb and anticipate change rather than resist itSeparate innovation from execution with intentional gates for when new approaches are ready to implementDocument your assumptions so you can revisit decisions effectively when circumstances changeFailure is a process problem, not a personal one—root cause analysis should improve systems, not assign blameData is the common language that aligns scientists, regulators, and stakeholdersEveryone is a leader in cell therapy—manufacturing and QC teams hold patient lives in their handsAbout Nelly ViseuxNelly Viseux is Vice President of Cell Therapies Development, Manufacturing, Supply & Quality at Regeneron, leading a 100-person organization supporting autologous cell therapy programs. She has over 20 years of biotechnology experience spanning large pharma (Shire, Biogen, Baxter) and startups, working across cell and gene therapies, biologics, and nanoparticles. Her accomplishments include building a Phase 1 cell therapy manufacturing facility that achieved 100% cGMP success and first IND submission within two years. She holds a Ph.D. in Biochemistry and Molecular Biology from University of Lille and is a member of the Society for Immunotherapy of Cancer and the American Society of Gene & Cell Therapy.About The FDA GroupThe FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle—from clinical development to commercialization—with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: ⁠⁠https://www.thefdagroup.com/

APAC stocks were ultimately mixed after the global market rout rolled over into the region following the continued tech woes stateside and weak US labour market data.US equity futures were lower but off worst levels with headwinds seen after Amazon shares dropped 10% post-earnings.European equity futures indicate an uneventful cash market open with Euro Stoxx 50 futures up 0.1% after the cash market closed with losses of 0.8% on Thursday.RBI maintained its Repurchase Rate at 5.25%, as expected, via a unanimous decision and voted to maintain its neutral policy stance; Banxico held rates at 7.00%, as expected, in a unanimous decision.Looking ahead, highlights include German Trade Balance (Dec), Swedish CPIF prelim. (Jan), Swiss Unemployment (Jan), Canadian Jobs Report (Jan), US Prelim. Michigan (Feb), ECB Survey of Professional Forecasters. Speakers include ECB's Cipollone, BoE's Pill & Fed's Jefferson.Earnings from Biogen, Under Armour, Carlyle Group, Philip Morris International, SocGen & Sabadell.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Javier Aledo, analista de AFI, sigue de cerca los escenarios de Amazon, Intel, Molina Healthcare, Biogen y Carlyle.

This INSIGHTS episode revisits a core topic from Neurocritical Care ON CALL®, originally released in August 2023.  Listen to the third episode of the NCS INSIGHTS series on acute ischemic stroke (part 1 of 2). The INSIGHTS series is hosted by Casey Albin, MD, and Salia Farrokh, PharmD, and covers topics from Neurocritical Care ON CALL®, the only up-to-date, comprehensive resource dedicated exclusively to the practice of neurocritical care. Learn more about ON CALL®. This episode is sponsored by Biogen. Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen. The NCS Podcast is the official podcast of the Neurocritical Care Society. The views expressed on the NCS Podcast are solely those of the hosts and guests and do not necessarily reflect the opinions or official positions of the Neurocritical Care Society.

In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Ahmed Enayetallah, PhD, MBBCh, Chief Development Officer at Dompé Farmaceutici, a company founded as the first compounding pharmacy in Milan, Italy, which has grown into a global biopharmaceutical company over 130 years. Currently, the company has a therapeutic pipeline focused on nerve growth factor (NGF)-based therapeutics in ocular diseases, including non-arteritic anterior ischemic optic neuropathy (NAION). Dompé has been a pioneer in translating NGF biology into medicine, building on decades of research by Nobel laureate Dr. Rita Levi-Montalcini. Dr. Enayetallah has a robust background in clinical research and deep expertise in drug development. His career has spanned several high-profile leading roles at pharmaceutical and biotechnology companies such as Amgen, Biogen, Pfizer and Alexion. He has led efforts in personalized medicine and oversaw multiple successful clinical programs that brought novel therapies to patients with high unmet needs. Prior to joining Dompé, he led the development organization at BlueRock Therapeutics. Dr. Enayetallah earned his medical degree from the University of Cairo and completed his PhD in Pharmacology and Toxicology at the University of Connecticut. Tune in to learn more about NGF biology and how it is being leveraged therapeutically in ocular diseases with high unmet need. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Amyotrofische laterale sclerose: waar staan we vandaag?In deze podcastaflevering duiken we in de nieuwste inzichten rondom amyotrofische laterale sclerose (ALS). Te gast is prof. dr. Jan Veldink, internationaal erkend ALS-expert en neuroloog, die zijn visie deelt op de complexe aard van deze ziekte. Hij neemt ons mee langs de verschillende klinische presentaties en varianten van ALS, en licht toe welke diagnostiek moet plaatsvinden.We gaan uitgebreid in op de pathofysiologie van ALS, de rol van TDP-43 als mogelijke diagnostische biomarker en de genetische factoren die bijdragen aan het ontstaan en beloop van de ziekte. Daarnaast bespreken we zowel de huidige als toekomstige therapeutische mogelijkheden.Tot slot krijgen we een persoonlijk inkijkje: met welke collega zou Jan Veldink graag een dag ruilen, en wat is zijn grootste passie naast het werk? Een aflevering die prikkelt, verdiept en uitnodigt om met een frisse blik naar ALS te kijkenDisclosures: JHV heeft lopende onderzoekscontracten gefinancierd door Biogen, Eli Lilly, Trace en Astra Zeneca. Zijn afdeling ontvangt funding vanuit NWO, ERC en Stichting ALS.

Host: Holly M. Brothers, PhD Guest: Niklas Mattsson-Carlgren, MD, PhD The prevalence of dementia is projected to almost double every 20 years.1 Alzheimer's disease (AD) is the most common cause of dementia,2 making early diagnosis and management increasingly important. Based on our current understanding of its pathology, AD is an amyloid driven tauopathy3 with biomarker changes occurring years before clinical symptoms appear.4 Learn more with this webinar featuring Dr Niklas Mattsson-Carlgren, Associate Professor at Lund University as he explores the relationship between amyloid beta and tau, the correlation between pathology and clinical symptoms, and biomarker progression across the AD continuum. To learn more about tau in Alzheimer's disease, explore the Know Tau medical education platform. Know Tau is created and funded by Biogen and is intended for healthcare professionals only. References: Alzheimer's Disease International. Numbers of people with dementia worldwide. Available from: https://www.alzint.org/resource/numbers-of-people-with-dementia-worldwide/ (Accessed June 2025) Alzheimer's Association. Alzheimer's disease facts and figures. Available from: https://www.alz.org/alzheimers-dementia/facts-figures (Accessed June 2025) Aksman LM, et al. Brain 2023;146:4935–4948 Jack CR Jr, et al. Alzheimers Dement 2018;14:535–562

South Africa’s toughest one-day mountain bike race returns on 17 January 2026, as the Momentum Medical Scheme Attakwas Extreme, presented by Biogen, celebrates its 20th edition. Africa Melane speaks to Co-founder & Financial Director at Dryland Event Management, Carel Herholdt.See omnystudio.com/listener for privacy information.

Dr. Christina Rahm has worked as a medical, clinical, and research scientist in the pharmaceutical, nutraceutical, and biotechnology industries for Janssen, Johnson & Johnson, Biogen Idec/Biogen, UCB, Bristol Meyers Squibb, and Alexion. Additionally, she worked on the corporate side for Pfizer, Biogen, and Janssen and is currently the Chairman of International Science Nutrition Society and Chief Science Officer for ROOT Wellness. Dr. Rahm has also served as a formulator for several companies and manufacturing labs, including her own. She has created multiple provisional patents, proprietary formulas, and trade secrets in addition to authoring her first book, Cure the Causes: Live the Life you Want, Not the One Prescribed. Through years of laboratory research and ethical observations, she has developed a personalized and predictive consulting company working on everything from the environment to DNA and detox wellness plans in which Dr. Rahm helps clients reset their bodies and minds to be spiritually, mentally, emotionally, and physically balanced.

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über einen Sam Altman im Attacke-Modus, die prominenten MDax-Aufsteiger und 7 Bücher, die Euch helfen, das globale Chaos besser zu verstehen. Außerdem geht es um Alphabet, Nvidia, Tencent, Softbank, T-Mobile, Nvidia, Arm, Biogen, Lululemon, ON Semiconductor, GlobalFoundries, CDW, The Trade Desk, Alnylam Pharmaceuticals, Seagate, Western Digital, Insmed, Monolithic, Ferrovial, Meta, Tesla, Apple, Microsoft, Broadcom, T-Mobile, Applovin, Palantir, Aumovio, TKMS, Hellofresh, Gerresheimer, Teamviewer, Ottobock, Tonies, Verbio, PSI Software, LPKF, Stratec, Thyssenkrupp Nucera, Formycon, Procredit, Amadeus Fire, iShares MSCI EM SRI ETF (WKN: A2AFCZ), Xtrackers MSCI World Health Care ETF (WKN: A113FD), L&G Cyber Security ETF (WKN: A14WU5), iShares STOXX Europe 600 Construction & Materials ETF (WKN: A0H08F), iShares Core MSCI World ETF (WKN: A0RPWH), (Xtrackers MSCI Emerging Market ETF (WKN: A12GVR), Amundi Core MSCI Japan ETF (WKN: LYX0YC), iShares Core MSCI Europe ETF (WKN: A0RPWG), Xtrackers MSCI USA ETF (WKN: A1XB5V), NASDAQ-100 ETF (WKN: A0F5UF), JPMorgan US Research Enhanced ETF (WKN: A2DWM7), Xetra-Gold (WKN: A0S9GB, Euwax Gold II (WKN: EWG2LD), iShares Global Corporate Bond EUR (WKN: A1W02Q), Xtrackers II EUR Overnight Rate ETF (WKN: DBX0AN). Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Launched in 2023, the European Commission's Comprehensive Approach to Mental Health is a holistic EU-wide strategy promoting prevention, access to care, and social inclusion, aiming to embed mental health across all policies and support well-being through early detection, assistance for vulnerable groups, and improved workplace mental health.Women's health is also gaining attention at the European level. This year, the European Parliament's health committee is set to launch an own-initiative report on a strategy for women's health, while the European Commission has published a Roadmap for Women's Rights calling for gender-sensitive healthcare to address health inequalities and gender-specific health risks.Postpartum depression (PPD) is a mental health condition affecting mothers after childbirth, and in severe cases can lead to suicide. It is the most common psychological condition after birth, affecting around 12% of mothers in Europe, yet it often goes undiagnosed and untreated due to stigma, lack of awareness, and insufficient support, leaving many women without the care they need. Despite growing attention on both women's and mental health, few EU-level initiatives specifically address PPD, highlighting the need for coordinated action and stronger policy support for maternal mental well-being.Listen to this Euractiv Hybrid Conference to discuss mental health in Europe, with a particular focus on women's health and postpartum depression. Questions to be addressed include:– How can the EU further embed mental health considerations across all policies to improve prevention, access to care, and social inclusion?– What steps are needed to strengthen women's health policies, including gender-sensitive healthcare and strategies to address health inequalities?– How can awareness, support, early detection and treatment of postpartum depression be improved across EU Member States?– What role can policymakers, patient groups, and other stakeholders play in strengthening policy action for maternal mental well-being?– Which policy initiatives or best practices could serve as a model for improving screening, diagnosis, and treatment of PPD?This is a Euractiv event funded by Biogen

Vinay Prasad's memo, leaked over the weekend, has sent vaccine makers' stocks slipping and experts clamoring for more evidence to support the CBER director's claim that COVID vaccines have led to the deaths of at least 10 children. It's the latest insult to the vaccine sector from the healthcare administration this year, with other challenges coming on the CDC side, where the recently revamped advisory committee is heading into its next meeting with a brand new chair.  Elsewhere at the FDA, newly promoted Center for Drug Evaluation and Research Director Richard Pazdur has filed the paperwork to retire from the agency just weeks after reportedly reluctantly accepting the position.   Meanwhile, the Alzheimer's space is buzzing as the 2025 Clinical Trials on Alzheimer's Disease (CTAD) conference continues in San Diego. Last week saw a mid-stage flop for Johnson & Johnson's anti-tau candidate and the “definitive” failure of Novo's GLP-1 semaglutide—which analysts say may actually help uptake of anti-amyloid therapies from Biogen and Eli Lilly. Meanwhile, Roche announced positive results for its latest antibody, putting the pharma back in the game it had once stepped back from in the tumultuous days of Aduhelm.   In the weight loss space, Novo Nordisk revealed ‘competitive' mid-stage data for its next-gen amycretin, which showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes. Meanwhile, the pricing war for approved and future GLP-1s from Novo and obesity rival Eli Lilly rages on, with Lilly this week announcing another price drop for Zepbound through its LillyDirect self-pay platform.  In BioPharm Executive this week, we review the top venture capital rounds for female-founded biotechs and examine the 2026 biotech market outlook. 

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of significant stories shaping the future of healthcare, from innovative financing strategies to groundbreaking scientific advancements.The biotech industry in 2025 has experienced a notable shift in funding strategies, particularly through the rising trend of royalty financing. This approach, involving the exchange of future drug revenue for immediate capital, has surged to approximately $3.5 billion in disclosed upfront volume in just the first half of the year. According to health economist Julien Willard, this represents a transformative shift from a niche option to a mainstream strategy amid challenging equity and credit markets. Royalty financing provides biotech companies with a lifeline, allowing them to avoid the pitfalls of equity dilution or high-interest debt while retaining control over their clinical developments. Firms like Royalty Pharma and Healthcare Royalty Partners are at the forefront, offering upfront cash for future sales royalties, typically ranging from 2.5% to 7.5%.This trend has accelerated due to economic pressures like low stock valuations and rising interest rates, making traditional funding routes less viable. A closer look at this year's deals reveals a cautious approach among investors, who are focusing on phase 3 trials or candidates awaiting FDA approval rather than early-stage assets. Oncology takes center stage as the leading therapeutic area, accounting for about 70% of total disclosed funding, thanks to its potential for large revenue streams. Other areas like rare genetic diseases and immunology also attract significant attention.Interestingly, even large pharmaceutical companies such as Biogen have ventured into royalty financing—an unconventional move for well-capitalized firms. Biogen's collaboration with Royalty Pharma for lupus drug development illustrates innovative financial engineering by transferring clinical trial risk through milestone-tied payments. As this strategy gains traction globally, especially in cash-strapped regions like Asia, it serves as a crucial tool for companies prioritizing survival and continued innovation amidst financial uncertainties.Turning now to regulatory dynamics and strategic shifts within the industry. The legal controversy between GSK's subsidiary Tesaro and AnaptysBio over Jemperli highlights complexities in collaborative agreements within drug development. Such disputes could reshape how companies negotiate intellectual property rights and revenue sharing in future co-development deals.The FDA's investigation into Takeda's Adzynma following a pediatric patient's death underscores the critical role of post-market surveillance in drug safety. This incident could potentially impact Takeda's market position while emphasizing the need for robust adverse event monitoring systems across biopharmaceutical firms.In Australia, the government's decision to block Cosette's proposed $430 million acquisition of Mayne Pharma reflects increasing scrutiny on foreign investments in healthcare companies, prioritizing national interest. This move signals a growing trend that could reshape global M&A strategies within the sector.Meanwhile, Moderna's strategic financial maneuvering is noteworthy. By securing a $1.5 billion loan aimed at supporting its commercial and R&D endeavors with an eye on breaking even by 2028, Moderna demonstrates its commitment to diversifying its mRNA technology applications beyond COVID-19 vaccines—a move likely to influence innovation trajectories across biotech landscapes. Additionally, Moderna's decision to discontinue three clinical mRNA programs showcases strategic pipeline management amidSupport the show

El experto de Apta Negocios analiza los títulos de Biogen, Apple, Acciona, ArcelorMittal e Indra, entre otros

This episode, hosts Heather and Matthew sit down with Nicole Murphy, Executive Vice President and Head of Pharmaceutical Operations and Technology at Biogen. Nicole shares why Biogen is growing in North Carolina with a $2 billion investment in Research Triangle Park, how the region's talent and infrastructure have fueled decades of innovation, and what's next for the company's late-stage clinical pipeline. We also explore how Biogen is using AI to accelerate drug development, the impact of federal price control policies, and why workforce development partnerships are key to the company's future. Tune in now!

This episode of the Scope of Things features an exclusive panel at SCOPE Europe 2025 covering regulatory requirements for AI literacy training, featuring industry executives Jonathan Crowther, head of the operational design center at Merck KGaA; Janie Hansen, global development information management, business systems transformation at Daiichi Sankyo; Francis Kendall, head of statistical programming, digital and data sciences at Biogen; and James Weatherall, vice president and chief data scientist of biopharmaceuticals R&D at AstraZeneca. Plus, host Deborah Borfitz gives the latest news on efforts to reduce excess data collection in studies, whole genome sequencing of breast cancer, a virus cocktail to combat superbugs, and more. Show Notes News Roundup   Collaborative study on data collection in trials News posted on the TransCelerate website Heart benefits of semaglutide Study in The Lancet Whole genome sequencing of breast cancers Study in The Lancet Oncology Pan-cancer immunotherapy heads to trials Research article in Cell Article in Bio-IT World Promising NAD+ “youth molecule” Review article in Nature Aging  Virus cocktail to combat superbugs Article in Nature Microbiology AI annotates medical images News posted on the MIT website Fitbits aid precision health American Life in Realtime study in PNAS Nexus Latest from the Human Epilepsy Project Study in JAMA Neurology Imposter study participants Editorial in The BMJ Guests Jonathan Crowther, Ph.D., Head, Operational Design Center, Merck KGaA, Darmstadt, Germany Janie Hansen, Global Development Information Management, Business Systems Transformation, Daiichi Sankyo Francis Kendall, Head of Statistical Programming, Digital and Data Sciences, Biogen James Weatherall, Ph.D., Vice President & Chief Data Scientist, BioPharmaceuticals R&D, AstraZeneca  The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

For TriloTalk episode 38, Lisa Chamberlain James, Senior Partner at Trilogy, and Sudipta Chakraborty, Head of Literacy & Plain Language Center of Excellence at Biogen, talk about how to use AI in the creation of lay summaries of clinical trial results. Scalability, change management, prompting, biases, realistic attitudes, and human involvement are all touched on so listen up! 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating advancements and strategic movements that are shaping the landscape of drug development and patient care.Starting with a significant milestone in precision oncology, China has approved its first EGFR-targeted antibody-drug conjugate. This approval marks a pivotal moment in the industry's shift towards targeted therapies, which promise more precise treatment options with potentially fewer side effects than traditional chemotherapy. Targeted therapies are at the forefront of personalized medicine, where treatments are tailored to individual genetic profiles, offering hope for more effective cancer care.In the realm of HIV prevention, Gilead Sciences has reported impressive sales for its new long-acting pre-exposure prophylaxis medication, Yetztugo. Since its launch in June 2025, Yetztugo has generated $54 million in U.S. sales, underscoring the demand for long-term HIV prevention solutions. This development is part of Gilead's broader strategy to strengthen its HIV franchise as it advances its pipeline with promising candidates like GS-3242 alongside lenacapavir. The aim is to develop treatments that require less frequent dosing, which could significantly improve patient adherence and outcomes. Despite challenges within its HIV portfolio and declining Veklury sales, Gilead Sciences is actively seeking growth opportunities through strategic partnerships and pipeline advancements—an essential approach for navigating patent cliffs while sustaining long-term growth.On the financial front, AbbVie has increased its revenue forecast by $400 million to a staggering $60.9 billion, driven by robust sales from its immunology drugs Skyrizi and Rinvoq. These treatments address chronic inflammatory conditions like psoriasis and rheumatoid arthritis, reflecting AbbVie's strong positioning in this therapeutic area despite competitive pressures. AbbVie continues to report strong earnings from Skyrizi and Rinvoq, reinforcing its dominance in the immunology market and highlighting the profitable nature of successful biologics in treating chronic inflammatory diseases.Biogen continues to bolster its multiple sclerosis franchise by focusing on both legacy treatments and new product launches. This strategy highlights the importance of balancing innovation with lifecycle management to maintain market strength against generic competition—a common challenge in the industry.Meanwhile, the American Academy of Pediatrics has taken a cautious stance by not endorsing leucovorin for autism treatment due to insufficient evidence. This decision emphasizes the critical need for rigorous, evidence-based practices in developing clinical guidelines for complex disorders like autism.Internationally, CSL Seqirus has partnered with Saudi Arabia to supply cell-based influenza vaccines and support local production capabilities. This move aligns with global efforts to enhance pandemic preparedness and healthcare resilience through local manufacturing initiatives.The volatile nature of the biotech sector is evident with reports of 16 companies ceasing operations in 2025 due to high R&D costs and regulatory challenges. Despite these closures, such volatility opens doors for new innovations that could address unmet medical needs.Turning our attention to obesity treatment, Eli Lilly stands at a crucial juncture with its novel obesity medication, orforglipron. The company aims to make this weight loss pill accessible while maintaining financial viability for future R&D—a balancing act faced by many pharmaceutical companies as they strive to deliver affordable yet innovative treatments amid growing global health concerns. However, not all R&D efforts reach fruition. Eli Lilly has decided to discontinue its mid-stage program Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the rapidly evolving landscape of the pharmaceutical and biotech sectors, where regulatory updates, strategic mergers, and scientific breakthroughs are continually reshaping the industry.Starting with Novo Nordisk's recent challenges, their newly acquired manufacturing facility in Indiana has been flagged by the FDA with an "Official Action Indicated" designation. This classification, being the most severe level of inspection categorization, potentially signals delays in production and collaboration with partners like Regeneron and Scholar Rock. Such regulatory hurdles underscore the vital importance of compliance in ensuring smooth supply chains and market availability of therapeutics. It's a stark reminder of how critical regulatory oversight is in maintaining quality assurance within pharmaceutical manufacturing.Meanwhile, Johnson & Johnson is navigating its own regulatory landscape by engaging with the Trump administration on drug pricing reforms. These discussions highlight the broader industry's ongoing efforts to adapt to evolving regulatory frameworks and market dynamics. By spinning off its orthopedics unit, J&J aims to sharpen its focus and drive growth in more strategic areas, illustrating a trend towards specialization as companies strive to align with market demands.In mergers and acquisitions news, BioCryst Pharmaceuticals has completed a significant $700 million acquisition of Astria Therapeutics. This move positions BioCryst to compete directly with Takeda's hereditary angioedema therapy, Takhzyro. The acquisition emphasizes the competitive nature of specialty markets and highlights how targeted acquisitions can expand therapeutic pipelines.Halozyme Therapeutics is similarly active in pursuing mergers and acquisitions to enhance its drug delivery capabilities. Their recent acquisition of Elektrofi aligns with Halozyme's strategy to innovate in drug delivery technologies, which are increasingly recognized for their role in improving therapeutic efficacy and patient experience.Funding models are also evolving within the industry as alternative programs for specialty drugs gain attention for their potential cost-saving benefits for self-insured employers. However, these models raise ethical concerns due to potential financial risks shifting onto patients. This ongoing debate underscores the complexity of balancing cost management with patient access in healthcare.BioNTech's initiative to establish mRNA vaccine production facilities in Africa represents a significant step towards enhancing vaccine accessibility and equity on a global scale. Supported by European Union funding, this move underscores the importance of regional manufacturing hubs in facilitating rapid distribution of life-saving vaccines.Turning our focus to clinical advancements, Roche and Eli Lilly's collaboration has led to FDA approval of an Alzheimer's blood test for primary care use. This diagnostic tool could significantly enhance the adoption of Alzheimer's treatments like Biogen's Leqembi by streamlining diagnosis processes in primary care settings.Novo Nordisk's Indiana facility has again made headlines due to FDA scrutiny, potentially impacting partnerships with major players such as Regeneron. This situation highlights how stringent compliance requirements can influence strategic partnerships and operational timelines.On a promising note, Kailera Therapeutics has raised $600 million in funding to advance its obesity treatment program into Phase 3 trials. With Bain Capital leading this round, it reflects investor confidence in targeting metabolic disorders—a growing area of focus given their widespread health implications.Artificial intelligence continues to reshape drug discovery processes. Takeda Pharmaceuticals' $1 Support the show

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Lars Petersen, President & Chief Executive Officer at FUJIFILM Biotechnologies.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lars, covering: The difficult decision to leave Novo Nordisk and make the jump from one great company to another in Genentech/Roche. How leaving a Biogen site led him to step away from big pharma after 25 years and transition to the CDMO side. How Fujifilm's culture of innovation, technology, quality, and people runs through the Biotechnologies division — and why empowerment and culture should never be compromised. Why the duplication of its CDMO sites globally, all running on the same kojoX platform, is truly differentiating. Why he believes the need to standardise, scale, and globalise drug production in a consistent, efficient, and traceable way is key to the future of the supply chain. Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate.    Lars Petersen, CEO of FUJIFILM Biotechnologies, is recognized as a visionary leader in the life science sector, commanding a global contract development and manufacturing organization (CDMO) with nearly 5,000 employees spread across Denmark, UK, USA, and Japan.    Distinguished for his strategic vision and a "people first" philosophy, Lars has profoundly impacted the company and the industry. His leadership journey saw him rise from Chief Operational Officer & Senior Vice President at the Danish site, where he established an empowering culture, to CEO, promoting transparency across all operations. Since his global leadership appointment in June 2023, Lars has been instrumental in cultural transformation, integrating a "people first" approach across FUJIFILM Biotechnologies' global facilities regardless of geographical differences.   Prior to his appointment as CEO, Lars was responsible for the Global Large Scale Commercial operation including full profit and loss accountability as well as the responsibility for over $6.2 Billion global expansions both in Hillerød, Denmark, and Holly Springs, North Carolina, USA.   Previously, Lars has held leadership positions with Biogen, Genentech/Roche, Novo Nordisk, Novozymes and NNE, and he has successfully executed projects in Europe, China and the US.   Lars holds a master's degree from the Technical University of Denmark.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BMZ865. CME/AAPA/IPCE credit will be available until September 25, 2026.From Screening Through Treatment: Proactive Engagement of Patients in Team-Based Care for PPD In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BMZ865. CME/AAPA/IPCE credit will be available until September 25, 2026.From Screening Through Treatment: Proactive Engagement of Patients in Team-Based Care for PPD In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BMZ865. CME/AAPA/IPCE credit will be available until September 25, 2026.From Screening Through Treatment: Proactive Engagement of Patients in Team-Based Care for PPD In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BMZ865. CME/AAPA/IPCE credit will be available until September 25, 2026.From Screening Through Treatment: Proactive Engagement of Patients in Team-Based Care for PPD In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BMZ865. CME/AAPA/IPCE credit will be available until September 25, 2026.From Screening Through Treatment: Proactive Engagement of Patients in Team-Based Care for PPD In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BMZ865. CME/AAPA/IPCE credit will be available until September 25, 2026.From Screening Through Treatment: Proactive Engagement of Patients in Team-Based Care for PPD In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Genmab has acquired Merus, a rising star in the field of oncology, for $8 billion. The acquisition includes Merus' bispecific antibody, petosemtamab, which targets EGFR and LGR5 and has shown potential for head-and-neck cancer. In other news, GSK CEO Emma Walmsley is stepping down after nine years, with Chief Commercial Officer Luke Miels set to replace her next year. The FDA's decision to disclose complete response letters in real-time has raised questions about transparency and the agency's role. Additionally, Biogen has shuffled staff after ending work on AAV, while Heidelberg has cut 75% of its staff after missed royalty payments.The FDA's real-time disclosure of complete response letters benefits investors by providing greater visibility into regulatory decisions. In September, the FDA's actions included boosting Keytruda while rejecting two spinal muscular atrophy therapies due to manufacturing issues. A judge's ruling on the FDA's authority over laboratory-developed tests reflects the impact of a recent Supreme Court decision. Six FDA decisions to watch for in Q4 could have significant implications for the biopharma industry and patients. Recent developments include positive results for an immuneering asset in pancreatic cancer, FDA approval for Lilly's oral SERD for breast cancer, and positive outcomes for uniQure's Huntington's therapy. Additionally, the FDA is streamlining development of cell, gene, and regenerative therapies. Other news includes the revival of a dormant drug as a potential autism treatment, setbacks in obesity studies, and unexpected rejections for certain therapies. Upcoming webinars and job opportunities are also highlighted.Listeners are encouraged to provide feedback on topics they would like to see covered in future episodes.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Uniqure's gene therapy for Huntington's disease, AMT-130, has shown promising results in a 3-year study, slowing disease progression by 75%. If approved, it would be the first genetic treatment for Huntington's. Meanwhile, Acadia Pharmaceuticals has discontinued a Prader-Willi drug after a late-stage failure. Biogen received an unexpected FDA rejection for a high dose of Spinraza, and J&J received a warning letter for violations at a Korean production plant. In the competitive bioscience industry, credentials from Biotility can help advance careers. Sanofi is investing in rare disease and neuro innovation, while Lilly is expanding manufacturing facilities. Scholar Rock faced setbacks with its spinal muscular atrophy drug.Chinese biotech has rapidly risen to become a global powerhouse, with companies making significant strides in oncology and other areas. However, despite this success, Chinese biotechs are facing financial challenges similar to those in the US. The influx of interest from big pharma has been a lifeline for these companies as they strive to prove themselves on the global stage. Akeso, a rising star in Chinese biotech, has developed potential blockbuster drugs and is valued highly in the market. However, President Trump's potential executive order restricting drug licensing deals in China could pose a threat to the progress made by Chinese biotechs. Despite these challenges, Chinese companies continue to perform well, with significant investments and partnerships driving growth in the industry. Pfizer's CEO emphasized the need for the US to focus on improving and competing with China rather than trying to slow them down. The future of Chinese biotech remains uncertain in the face of geopolitical tensions, but the industry continues to innovate and attract investment from pharmaceutical companies worldwide.

Un inventor de Huesca presenta EcoFire, un producto ignífugo cuya verificación se solicita. Francia vive masivas protestas contra el ajuste presupuestario, con disturbios y cierres. La Fiscalía española investiga violaciones de derechos humanos en Gaza y Trump visita el Reino Unido. Aumentan las condenas por delitos sexuales en España. COPE informa sobre el 'Caso Negreira', con declaraciones de expresidentes del Barcelona, y el partido del Barcelona en Champions. El sistema Biogen, para el seguimiento de maltratadores, presenta graves fallos que comprometen la seguridad de las víctimas. A un año de la Dana en Valencia y cuatro de la erupción del volcán de La Palma, persisten las consecuencias y se critica la gestión de ayudas. El Gobierno de Sánchez intensifica los anuncios diarios en un contexto de hiperactividad política, mientras Zapatero busca apoyo de Puigdemont en Suiza. Los niños en España reciben móviles cada vez antes, generando riesgos en adolescentes por el uso de redes ...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novartis and Monte Rosa have entered into their second molecular glue deal worth up to $5.7 billion, with Novartis putting $120 million upfront for more of the biotech's AI-discovered degraders. The myasthenia gravis market, once sparse, is now flourishing with new treatments approved and promising late-stage trial results from companies like Argenx and Regeneron. In other news, AstraZeneca has suspended its $270 million commitment in the UK, the FDA has flip-flopped on scrapping advisory committee meetings, and Sino Biological has developed a high-throughput platform for AI-driven antibody discovery. The myasthenia gravis space is heating up with targeted therapies, with several companies releasing promising late-stage trial results. Biogen is developing a pipeline for lupus, with investors showing interest in their programs. The FDA has several actions scheduled for September, including Merck's proposed subcutaneous formulation of Keytruda. Eli Lilly's obesity pill, Orforglipron, is in focus at the European Association for the Study of Diabetes meeting. In the cancer news, Merck's Keytruda challenger faces consistency problems, while other companies like Daiichi Sankyo and Biontech report positive data. Capsida reports a patient death in a gene therapy trial, while Alkermes shows promise in narcolepsy treatment. FDA is looking to streamline the development of non-opioid painkillers. Various webinars and events are upcoming in the pharma industry. Job opportunities are available at companies like Moderna, Abbvie, and Regeneron. Overall, the biopharma industry is seeing advancements and progress in various therapeutic areas.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Novartis recently acquired Tourmaline for $1.4 billion, continuing its investment in cardiovascular treatments. The company has also made other partnerships in the cardiovascular space this year. Biogen is preparing to release new data on its lupus treatments, with analysts praising the company's pipeline. Novartis has been active in mergers and acquisitions, putting over $17 billion into deals this year. The biotech industry is also seeing some activity, with LB filing for a $228 million IPO to support its phase III plans. Overall, companies like Novartis and Biogen are focusing on expanding their portfolios and developing innovative treatments for various diseases.

This podcast and accompanying promotional content has been created in collaboration with and funded by  Biogen. This information is intended for healthcare professionals. The presented content includes mentions of the Skyclarys▼ (omaveloxolone) EU-approved label. Prescribing information for omaveloxolone can be found here. Friedreich's ataxia (FA) is a rare genetic disease that can affect children and adults and cause progressive neurodegeneration, loss of physical function, multiple comorbidities, and even premature death. In this episode, two well renowned experts, Dr Louise Corben and Dr Wolfgang Nachbauer discuss the diagnostic journey for patients with FA, disease progression and the importance of working with multidisciplinary teams in the development of management strategies.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has successfully reduced cardiovascular risk by 57% compared to tirzepatide. Eli Lilly has terminated two mid-stage trials for a second obesity asset, while Vertex Pharmaceuticals and Enlaza Therapeutics have formed a potential $2 billion partnership to develop drugs for autoimmune diseases. Biogen and Eisai have received FDA approval for the subcutaneous maintenance formulation of Leqvembi. Arrowhead Pharmaceuticals has secured a commitment of up to $2 billion from Novartis for an siRNA Parkinson's program. The FDA's new radiopharma guidance is expected to accelerate the space, and Teva has launched the first generic version of Novo Nordisk's obesity drug Saxenda. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies focusing on innovation and new partnerships to drive progress.The FDA has issued new radiopharma guidance, which former FDA Commissioner Stephen Hahn believes is crucial for cancer therapy. Despite recent investments in radiopharmaceutical therapeutics by big pharma, the FDA's approval of updated COVID-19 vaccines with restrictions contradicts the medical freedom promised by health secretary Robert F. Kennedy Jr. Rare diseases secured four FDA firsts in August, including a win for Novo Nordisk's glp-1 drug WeGovy. Investment in new ALS therapies signals progress after setbacks, with new biotechs and collaborative initiatives showing promise at Bio2025. Other news includes the closure of Appia, Senate summons of Kennedy, updates on COVID-19 vaccines, and Lilly's obesity pill heading to the FDA. Thank you for listening to Pharma and Biotech daily.

After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second quarter. In this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy break down the numbers behind the industry’s second-quarter performance. Among U.S. pharma heavyweights, J&J, AbbVie, Pfizer, Regeneron, Bristol Myers Squibb and Biogen each eked out gains this past quarter. Their results varied, with individual stories worth highlighting at each of these major companies. Beyond earnings, Sagonowsky and Dunleavy also discuss the growing competition in diabetes and obesity treatments between Eli Lilly and Novo Nordisk, as well as Merck’s rising financial reliance on its blockbuster cancer drug Keytruda, among other topics. To learn more about the topics in this episode: Several US pharma giants stage Q2 sales turnaround after subpar results earlier in year The battle of the obesity drug heavyweights 7 top pharmas posted revenue declines in Q1. The common thread? All are US firms Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview See omnystudio.com/listener for privacy information.

Greg and Matias interview Brendon Boot of Skin2Neuron. Brendon is a neurologist at Harvard and Mayo Clinic with prior experience as Medical Director at Biogen overseeing their Phase 1b Alzheimer's trials.In this episode, we discuss:How skin-derived cells can be turned into neurons to repair the brain.Why replacing lost neurons may succeed where drugs have failed in Alzheimer's.What makes autologous (self-derived) cell therapy safer and more effective.How testing in dogs brought stronger proof than traditional mouse models.Why this approach could shift Alzheimer's treatment from slowing decline to restoring memory.Credits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Caitlin Ner & Nico V. Rey Find us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Vinay Prasad has returned to his position as director of the Center for Biologics Evaluation and Research at the FDA after a sudden exit less than two weeks ago. The FDA has restricted the patient pool for bluebird's Skysona gene therapy due to safety concerns, and Sarepta's AAV gene therapy platform has come under scrutiny following patient deaths from liver injuries. Genscript is celebrating a new era of innovation and trust.The text discusses the scrutiny faced by AAV gene therapy technology following patient deaths related to Sarepta Therapeutics' platform. There is a push for improvement in the technology, while some are looking to move on to other options. The article also highlights the importance of mRNA technology in cancer research and the need for continued investment in this area. Additionally, it mentions the FDA's decision on Biogen and Eisai's Alzheimer's drug, as well as five oral obesity drugs that could rival Lilly's Orforglipron. Other topics covered include cancer drug developments, gene therapy news, and upcoming industry events.Stay tuned for more updates on the latest news in the pharmaceutical and biotechnology industries.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Biogen's sales of the partnered Alzheimer's drug Leqembi have climbed 20% in the second quarter, while CEO Chris Viehbacher dismisses rumors of disagreements with Eisai. Moderna has cut 10% of its global workforce as part of cost-cutting measures. AbbVie is celebrating the success of Skyrizi and Rinvoq, Lilly's Mounjaro shows promise in a cardiovascular trial, and there is optimism around Sarnas for therapeutic breakthroughs. Amidst industry challenges, many biopharma professionals are looking for new job opportunities.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Vinay Prasad's departure from CBER has analysts anticipating a more traditional successor, while GSK streamlines its pipeline and pledges billions in US investments. Susan Monarez is now the confirmed CDC director, and the top biopharma venture capital raises of H1 2025 are summarized. Despite challenges like layoffs and market fluctuations, GSK remains committed to investing in the US despite tariffs. Other headlines include Madrigal's potential $2 billion investment, Biogen and Eisai's Alzheimer's drug update, and Novo Nordisk's new leadership. Trilink Biotechnologies is offering self-amplifying RNA constructs for potential therapeutic advancements.AI biotech companies have secured substantial funding in the first half of 2025, with continued investment pouring into startups within the industry. The top five biopharma venture capital raises of this period are highlighted. There is confusion surrounding Ira's definition of 'drug,' potentially hindering companies from pursuing approval for new formulations and indications. Vinay Prasad's departure from the FDA's Center for Biologics Evaluation and Research, following controversies related to Sarepta, has raised concerns among developers. Despite challenges, four biotech companies are successfully launching their products independently.Over 260 million people are impacted by rare diseases, emphasizing the need for faster evidence generation through global real-world data. GSK's commitment to investing in the US, Merck's cost-cutting measures to support its launch schedule, and Novo Nordisk's new leadership are also highlighted. The FDA has updated regulations regarding Sarepta's DMD gene therapy, making it available for ambulatory patients. Adaptimmune anticipates significant staff reductions following a cell therapy asset sale. Stay tuned for more updates on the latest developments in the biopharma industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sarepta Therapeutics has halted the distribution of Elevidys in the US after the FDA request, following two deaths. The company's transparency has been called into question, affecting its stock value. Replimmune also faced setbacks after the FDA rejected its melanoma treatment, causing a significant drop in shares. On a more positive note, AstraZeneca has pledged $50 billion for US manufacturing, focusing on drugs like Baxdrostat and oral glp-1 therapies. Sanofi has made a $1.6 billion vaccine acquisition, while Biogen commits $2 billion to expand US drug production. The pharmaceutical industry is seeing various developments and challenges, with companies adapting to regulatory demands and market pressures.

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über einen Mega-Deal von Lucid, Billionen-Träume bei Netflix und den Absturz von Jungheinrich. Außerdem geht es um Quantumscape, Bigbear.AI, Aeva Technologies, D-Wave, Archer Aviation, Intuitive Machines, Rocket Lab, AST Spacemobile, Netflix, Disney, ComCast, Warner Brothers Discovery, Uber Technology, Interactive Brokers, TSMC, ASML, PepsiCo, Taiwan Semiconductor, Novartis, Richemont, ABB, Siemens, Salzgitter, Burberry, American Express, Tema Neuroscience and Mental Health ETF (WKN: A408EL), Vertex Pharmaceutical, Eisai, Biogen, Eli Lilly, DexCom, Siemens Healthineers, Johnson&Johnson, Pfizer, Lindbeck, GSK, Atai Life Science, Mind Medicine, iShares Core MSCI World (A0RPWH), Xtrackers MSCI World USD (A1XB5U), Vanguard FTSE All-World USD (A2PKXG), Xtrackers AI & Big Data (A2N6LC), Amundi MSCI World USD (ETF146), Amundi Core Stoxx Europe 600 (LYX0Q0), iShares MSCI ACWI (A1JMDF), Xtrackers II EUR Overnight (DBX0AN), WisdomTree Europe Defence ETF (A40Y9K), HanETF Future of Defence ETF (A3EB9T). Habt Ihr suizidale Gedanken, oder habt Ihr diese bei einem Angehörigen/Bekannten festgestellt? Hilfe bietet die Telefonseelsorge: Anonyme Beratung erhält man rund um die Uhr unter den kostenlosen Nummern 0800 / 111 0 111 und 0800 / 111 0 222. Auch eine Beratung über das Internet ist möglich unter http://www.telefonseelsorge.de. Eine Liste mit bundesweiten Hilfsstellen findet sich auf der Seite der Deutschen Gesellschaft für Suizidprävention. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this solo update, host Andrew Walker revisits his three 2025 stock ideas (disclosure: long all three!): Sage Therapeutics (SAGE), Keros Therapeutics (KROS), and Full House Resorts (FLL). He breaks down Sage's acquisition by SUPN and the chance of a higher bid from Biogen, discusses Keros' announced capital return, and digs into why Full House Resorts has lagged so far despite promising insider buying and strong project progress. Andrew also highlights why active shareholder engagement still matters and how insider moves can reveal conviction.For links to the prior podcast ideas and open letter, please see this post: https://www.yetanothervalueblog.com/p/midyear-2025-podcast-ideas-updatesChapters[00:00:00] Andrew opens midyear update.[00:01:00] Recaps Sage, Keros, Full House.[00:07:33] Sage sold, Biogen topping bid?[00:14:27] Keros capital return progress is slow.[00:18:44] Full House lagging; insider buying.[00:27:59] CEO massive buy from ex-wife.[00:30:30] Refinancing risk key catalyst ahead.Links:Yet Another Value Blog: https://www.yetanothervalueblog.com See our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimer

Synopsis: When an introverted engineer becomes the President & CEO of REGENXBIO, transformation follows. Curran Simpson joins host Rahul Chaturvedi to unpack his unlikely journey from biotech operations to the C-suite—and how that hands-on experience is reshaping gene therapy's future. They dive into the evolution of REGENXBIO's pipeline, tackling ultra-rare diseases like MPS II, ambitious plans for Duchenne Muscular Dystrophy, and commercial partnerships with giants like AbbVie. Curran offers hard-earned leadership lessons, honest reflections on scaling science, and insights into how one-time gene therapies could revolutionize treatment in both rare and common diseases. From clinical nuance to strategic boldness, this is a masterclass in biotech leadership, platform focus, and staying patient-first—no matter how complex the science or market. Biography: Curran M. Simpson is the President and Chief Executive Officer and member of the Board of Directors at REGENXBIO. Mr. Simpson previously served as the Company's Chief Operating Officer. In that role, he led key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations and served as the Company's Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO of Human Genome Sciences (HGS), where he led the integration of HGS into GSK, and as Senior Vice President of Operations and Vice President of Manufacturing Operations at HGS. Prior to HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen. Earlier in his career, Mr. Simpson served in an overseas assignment at Novo-Nordisk Biochem in Denmark and in various senior development and engineer roles at Genentech, working on Herceptin and Avastin, among other roles. Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemistry from the Clarkson College of Technology.

Christina Rahm, MS, PhD, EdD, is an internationally recognized entrepreneur, scientific leader, spokesperson, and innovator in the health and wellness space. Her overall approach to her groundbreaking work is to dismantle the barriers blocking the way to optimal health by identifying the root causes of issues and then addressing them scientifically and holistically.Full Podcast Link https://bit.ly/DrChristinaRahmPodcast A living embodiment of her motto, "The most important environment is yours," she travels the world presenting, lecturing, and educating the private and public sectors about the bold new world of nutraceuticals, wellness strategies, and environmental solutions, ultimately paving the way for the advancement of humanity. With multiple master's-level, doctoral-level, and honorary doctorate degrees in the fields of rehabilitation counseling, psychology, philosophy, and strategic sciences, Dr. Rahm also holds certifications from Harvard and Cornell in nanotechnology, nutrition, and pharmaceutical management. In addition to helming her own far-reaching enterprises, she has served as a medical, clinical, and research scientist for such notable pharmaceutical and biotechnology labs as Johnson & Johnson, UCB, Alexion, and Bristol Myers Squibb, and she has worked on the corporate side for Pfizer, Biogen, and Janssen, among others. A wife, mother, author, scientist, formulator, artist, influencer, and humanitarian, Christina Rahm is a powerhouse of energy and focus, devoted to human progress in all its forms and driven to contribute to positive change across the planet.

In this CME podcast episode, Dr. Andrew Cutler interviews Dr. Phillip Coffin, Director of the Center on Substance Use and Health in San Francisco, CA, about the management of stimulant use disorders. They explore the challenges of treatment and highlight the importance of harm reduction strategies to enhance patients' quality of life.  CME credit is available to NEI Members only.   Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Summarize pharmacologic and behavioral treatment strategies for stimulant use disorders, particularly methamphetamine and cocaine Evaluate the evidence base for current and investigational medications used in clinical trials and real-world settings Apply harm reduction principles and integrated care models to improve outcomes for patients with stimulant use disorders in diverse clinical settings Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: June 18, 2025*   Expiration: June 17, 2028 *NEI and HMP Education maintain a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-02.  Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until June 17, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Peer Review: The content was peer-reviewed by an MD, LFAPA specializing in psychiatry, forensic, addiction to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Phillip Coffin, MD, MIA Director of Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, CA No financial relationships to disclose. The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, Stephen Daniels and Bahgwan Bahroo, MD, LFAPA. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.